Scholarlink

Background <p>Abemaciclib, a selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, is standard adjuvant therapy for hormone receptor (HR)-positive, HER2-negative early breast cancer. While gastrointestinal and haematologic toxicities are well recognised, cardiotoxicity—particularly myocarditis—is extremely rare. To our knowledge, myocarditis has not previously been reported in early breast cancer. This case describes a case of acute abemaciclib-induced myocarditis and explores a potential genetic predisposition involving an <i>RHBDF2</i> germline variant affecting growth factor signalling pathways.</p> Case presentation <p>A 39-year-old female with high-risk HR-positive, HER2-negative early breast cancer commenced adjuvant abemaciclib with letrozole following completion of chemotherapy and radiotherapy. Within 24 h, she developed acute chest pain with an elevated troponin I (8457 ng/L), new T-wave inversion on her ECG, and a reduced left ventricular ejection fraction (47%) on echocardiography. CT imaging excluded coronary or aortic pathology. Cardiac magnetic resonance imaging demonstrated mid-inferoseptal late gadolinium enhancement consistent with acute myocarditis. Abemaciclib was immediately discontinued, and bisoprolol and ramipril were initiated. Her symptoms and cardiac function improved rapidly, with normalisation of left ventricular ejection fraction (68%). Genetic testing identified a germline RHBDF2 missense variant, which is predicted to alter tumour necrosis factor alpha and epidermal growth factor signalling, potentially predisposing to cardiomyocyte injury based on published in vitro evidence.</p> Conclusions <p>To our knowledge, this is among the earliest reported cases of abemaciclib-induced myocarditis in early breast cancer. Awareness of this potential toxicity is crucial, as early recognition and management is pivotal to prevent lasting cardiac dysfunction. Genetic variants influencing inflammatory or growth factor pathways may contribute to individual susceptibility, warranting further investigation. This case highlights the importance of combined cardio-oncology care in the early recognition of cardiotoxicity when introducing CDK4/6 inhibitors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Abemaciclib-induced myocarditis in early breast cancer: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月14日

查看全文
  • Alexander JP Fulton,
  • Mun Cheang,
  • Maria TA Wetscherek,
  • Paul Cacciottolo,
  • Jean E Abraham

摘要

Background

Abemaciclib, a selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, is standard adjuvant therapy for hormone receptor (HR)-positive, HER2-negative early breast cancer. While gastrointestinal and haematologic toxicities are well recognised, cardiotoxicity—particularly myocarditis—is extremely rare. To our knowledge, myocarditis has not previously been reported in early breast cancer. This case describes a case of acute abemaciclib-induced myocarditis and explores a potential genetic predisposition involving an RHBDF2 germline variant affecting growth factor signalling pathways.

Case presentation

A 39-year-old female with high-risk HR-positive, HER2-negative early breast cancer commenced adjuvant abemaciclib with letrozole following completion of chemotherapy and radiotherapy. Within 24 h, she developed acute chest pain with an elevated troponin I (8457 ng/L), new T-wave inversion on her ECG, and a reduced left ventricular ejection fraction (47%) on echocardiography. CT imaging excluded coronary or aortic pathology. Cardiac magnetic resonance imaging demonstrated mid-inferoseptal late gadolinium enhancement consistent with acute myocarditis. Abemaciclib was immediately discontinued, and bisoprolol and ramipril were initiated. Her symptoms and cardiac function improved rapidly, with normalisation of left ventricular ejection fraction (68%). Genetic testing identified a germline RHBDF2 missense variant, which is predicted to alter tumour necrosis factor alpha and epidermal growth factor signalling, potentially predisposing to cardiomyocyte injury based on published in vitro evidence.

Conclusions

To our knowledge, this is among the earliest reported cases of abemaciclib-induced myocarditis in early breast cancer. Awareness of this potential toxicity is crucial, as early recognition and management is pivotal to prevent lasting cardiac dysfunction. Genetic variants influencing inflammatory or growth factor pathways may contribute to individual susceptibility, warranting further investigation. This case highlights the importance of combined cardio-oncology care in the early recognition of cardiotoxicity when introducing CDK4/6 inhibitors.